Developed low dose vaccine to prevent nCoV

CureVac can produce a billion doses of nCoV vaccine from existing facilities if the trial is successful.

With a budget of US $ 8.3 million from the Alliance for Disease Control Initiatives (CEPI), a biotechnology company in Tuebingen, Germany is developing low-dose vaccine technology to cope with nCoV. According to CureVac, the test vaccine will be ready for use in June or July. After that, the company will ask the authorities to issue a test permit for human use.

Picture 1 of Developed low dose vaccine to prevent nCoV
Researchers at Curevac develop a nCoV vaccine in a laboratory in Turbingen on March 12.(Photo: Reuters)

"Nature has created mechanisms to activate the immune system against infectious diseases. With mARN (genetic information) technology , we mimic nature, providing the body with information on how to fight." With the combination of mARN technology, knowledge of the disease, expertise in vaccine preparation and production, CureVac can join the battle with all infectious diseases, regardless of whether it is a seasonal disease or a pandemic. , " Shared Mariola Fotin-Mleczek, chief technology officer of CureVac.

CureVac views mARN as one of the most potential molecules that provides a quick and effective solution when an outbreak occurs. The company has 20 years of experience developing and optimizing mRNs for medical service. This type of RNA carries information that instructs the body to produce proteins against many diseases. CureVac has applied this technology to develop cancer therapies, antibody therapies, rare diseases and vaccines.

Earlier, the company announced that it had successfully tested the vaccine against rabies with two doses of 1microgram (equal to 0.000001 grams). Currently, CureVac is expanding production facilities to be able to provide a billion doses of vaccine in the Covid-19 epidemic.